Kidron Nadav

Avg. Two Year Performance

27% Avg. Purchase Return
13% Compound
< 1% Avg. Sale Return
0% Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return57%37%15%37%27%
Purchase Success Rate3 of 43 of 41 of 43 of 42 of 4
Average Sale Return< 1%< 1%< 1%< 1%< 1%
Sale Success Rate1 of 21 of 21 of 21 of 21 of 2

Oramed Pharmaceuticals Inc.

Drugs » Biotechnology

President and CEO, Director:

Holdings: 1.91M shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--